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ABSTRACT 
Several populations of progenitor cells have been identified in the adult heart, 
based on the expression of specific surface markers (c-kit, Sca1, SSEA1, Isl-1), or on 
functional properties such as the ability to expel a vital dye (Side Population) or to 
spontaneously migrate from tissue explants and grow in three dimensional 
structures called cardiospheres (CSps), representing a niche-like microtissue with a 
cardiogenic gradient of differentiation. It is not clear which is the origin of these 
endogenous progenitor populations and how they function in vivo, given the 
limited regenerative capacity of the heart. Several possibilities can be envisioned. 
These cells could be remnants of the embryonic development, or derive from the 
de-differentiation of cardiomyocytes. A better understanding of their biological 
meaning is important not only for the extension of our knowledge in the field, but 
also to gain insight on the regenerative potential and differentiative fate of the cells 
for the clinical translation of cell therapy. To deeply investigate these issues, we 
approached the question from two different sides. Firstly to test the de-
differentiation  hypothesis, we used a double transgenic mouse expressing the 
recombinase MerCreMer under the α- Myosin-Heavy-Chain promoter, specific of 
differentiated cardiomyocytes, thus a pulse with 4-OH-tamoxifen (TAM) would 
activate Cre , allowing the expression of the reporter gene LacZ, in a spatial and 
temporal regulated manner. With this system, ideally all the differentiated 
cardiomyocytes should be irreversibly labeled after TAM treatment, even if they 
subsequently undergo de-differentiation. B-gal positive cells resulted very rare in 
culture, as shown by x-gal staining and real time PCR, suggesting that 
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cardiomyocytes de-differentiation is not the main mechanism underlying the 
presence of immature cells within the CSps, nor their formation, even though, given 
the limited sensibility of the method, (the efficiency of recombination in the 
cardiomyocytes is 80% at maximum) the occurrence of this phenomenon cannot be 
conclusively excluded. Then, we explored the potential of the epicardial-derived 
cells as contributors/founders of our in vitro-derived regenerative system that is 
the CSps. The epicardium, in fact, is crucial for a normal development of the heart, 
given its double role as source of multipotent mesenchymal progenitors and of 
instructive soluble signals that stimulate coronary vessel development, as well as 
cardiomyocyte proliferation and differentiation. Using another transgenic mouse 
strain, in which epicardial and epicardial-derived cells are labeled, we observed a 
large number of positive cells at all culture stages. Our hypothesis, supported by 
RT-PCR data, is that epicardial-derived cells undergo mesenchyma-to-epithelium 
(MET) transition during CSps formation, reactivating their embryonic 
developmental program. This is in line with a recent report presenting MET as a 
crucial mechanism in cell reprogramming. The information acquired in this work of 
thesis, although in need to be supported by future in vitro and in vivo experiments, 
represents a starting point for a better evaluation not only of the biological 
meaning of the heart-tissue-derived cardiac regenerative cells in the form of CSps, 
but also for the prevision of their in vivo fate once translated in clinic as therapeutic 
tools. 
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INTRODUCTION 
The adult heart as a terminally differentiated organ 
The mammalian adult heart has long been considered as a terminally differentiated 
organ, a view supported by clinical observations: primary myocardial tumors are 
rarely observed in adults and significant myocardial injury results in a permanent 
reduction in cardiac performance.  
Cellular loss in adult myocardium (caused by ischemia, genetic mutations, viral 
infections, drug abuse, chemotherapy, etc.) does not result in an efficient 
regeneration, but in deposition of non contractile fibrotic tissue. The reparative 
response can be divided in three overlapping phases [1] (fig.1.1). During the 
inflammation phase, cells in and around the affected areas upregulate and secrete 
cytokines and chemokines such as tumor necrosis factor-α (TNF-α), monocyte 
chemoattractant protein-1 (MCP-1),interleukin (Il)-1β, Il-6 or Il-8, which trigger an 
immediate and massive infiltration of circulating leukocytes into the ischemic core 
[2]. Adjacent endothelial cells bolster the recruitment of pro-inflammatory immune 
cells by upregulating their expression of cell adhesion molecules such as E-selectin, 
intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 
(VCAM-1). The initial wave of infiltrating cells is followed by monocytes that home 
to the damaged area and mature into macrophages. The immune cells gradually 
clear out cellular debris and matrix degradation products in the injury site, leaving 
behind sparse tissue with enlarged capillaries. As the acute inflammatory response 
is suppressed, the gap left behind is filled by granulation tissue. Mesenchymal cells 
infiltrate the infarct marking the transition to the proliferative phase[2]. 
Myofibroblasts deposit extracellular matrix while a rich capillary network is formed. 
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During the maturation phase the cellularity of the granulation tissue (mainly 
composed of blood vessels, macrophages and myofibroblasts) decreases and the 
matrix is cross-linked forming a dense collagen-based scar. The ischemic area is rich 
in inflammatory cytokines and protease activity, which harms surrounding healthy 
cells [3]. The extra-mechanical burden on the remaining ventricular cells further 
compromises the integrity of the cardiac tissue. Thus, the initial localized injury 
creates a ripple effect that spreads slowly to larger areas of the heart. The loss of 
functional tissue and subsequent remodeling eventually causes ventricular 
dysfunction and electrical instability, leading to heart failure and malignant 
arrhythmias [4]. Current treatments provide some survival benefits and 
amelioration of symptoms, but they do not recover function of the damaged tissue. 
The only routinely used therapeutic approach to replace the injured tissue is heart 
transplantation, which is a last chance treatment given the limited donors’ pool.  
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Figure 1.1. Phases of infarct healing [1] 
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Evidences of cardiac renewal in post natal hearts 
In the past 10 years, evidences have shown that the mammalian heart is endowed 
with a limited regenerative potential and turnover capacity, starting from the 
observation of cycling myocytes in the adult heart, both in physiological and 
pathological conditions [5, 6].  In an elegant genetic fate mapping experiment [7], 
using transgenic mice in which differentiated cardiomyocytes would permanently 
express the GFP reporter, it has been shown that, in response to an injury, the 
cardiomyocyte pool (GFP+ cells) in the adult heart is significantly replenished by 
cells that were undifferentiated (GFP-) at the time of the injury, while the 
percentage of GFP-labeled cardiomyocytes is nearly unchanged during physiological 
ageing.    
Another recent study [8], analyzing cell cycle markers on FACS sorted nuclei from 
cTnT positive cells, support the evidence of cardiomyocytes cell cycle withdrawal 
soon after birth in mice. By day 14 proliferating cardiomyocytes could not be 
detected and almost 98% of them were bi-nucleated. 
However the regenerative capacity seems to differ among different species, in fact 
in humans the adult myocardium displays proliferating cardiomyocytes and less bi-
nucleation (30-65%) compared to the adult mouse, suggesting a prolonged coupling 
of karyokinesis with cytokinesis, which leads to cell renewal.  
Indeed, through the use of radiocarbon dating of human postmortem cardiac tissue 
[9], it has been confirmed that cardiomyocytes undergo turnover in the adult 
human heart with an annual rate of about 1% in young adults, declining below 
0.45% by the age of 75. It is not clear yet, which is the mechanism involved. 
Therefore cardiomyocyte turnover may occur through multiple not exclusive 
mechanisms, including cell-cycle re-entry and dedifferentiation of cardiomyocytes, 
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differentiation of endogenous cardiac progenitor cells (CPCs), or circulating 
progenitors recruited from the bone marrow (BM) [10].  
 
 
Figure 1.2. Possible cell sources and mechanisms for cardiomyocytes turnover and regeneration in 
physiological and pathological conditions [10] 
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Potential sources of cardiac regeneration 
Cardiomyocytes de-differentiation 
Some vertebrates, like urodeles and zebrafish, are able to regenerate significant 
portions of the heart and similar mechanisms are involved in blastema’s formation. 
After amputation a blood clot seals the injury site, then the clot matures into fibrin 
and fibroblasts and inflammatory cells are attracted to the site. Starting from the 
edges of the wound new cardiomyocytes are formed, regenerating the myocardial 
tissue [11, 12]. In newt, it has been demonstrated that cardiomyocytes are the 
main responsibles for myocardial regeneration. In fact a subset of cardiomyocytes 
[13] can partially dedifferentiate into a progenitor-like state, expand and then re-
differentiate in cardiac cells.  
Two recent reports [14, 15], based on lineage tracing systems, have shown that 
even in zebrafish the regeneration mostly relies on a subset of pre-existing 
differentiated cardiomyocytes, rather than on progenitor cells as previously 
suggested [16]. Cardiac damage induces a widespread activation of the epicardium 
which produces important factors for neovascularization and reactivation of a 
subset of subepicardial GATA4-positive cardiomyocytes within the ventricular wall. 
As in newt, proliferating cardiomyocytes undergo limited dedifferentiation: they 
start to detach from one another and to disassemble their sarcomeric structure 
with a concomitant down-regulation of sarcomeric genes and reactivation of cell 
cycle regulatory genes, such as plk1 and mps1.  
In mammalian hearts during fetal development, cardiomyocytes are able to go 
through mitosis by continuous disassembling and reassembling of their contractile 
apparatus [17, 18]. However cell cycle withdrawal is gradually achieved while 
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reaching the end of gestation and this corresponds to the maturation of the 
cardiovascular system, achieving higher blood pressure levels. After birth, the 
increase in heart mass (about 30-50 fold from birth to adulthood [19]) is due to 
hypertrophy rather than cell division [20]. In the first ten years of human life 
cardiomyocytes are reported to undergo  karyokinesis in the absence of cytokinesis 
resulting in bi-nucleation and polyploidy [8].  
It is interesting, however, that even in humans, after an injury, hibernating 
cardiomyocytes show similar structural changes: depletion of sarcomeric structure 
and expression of structural proteins closely resembling that of fetal heart cells, as 
if cardiomyocytes could initiate the first step toward proliferation, but 
subsequently face a block in the cell cycle. A recent study [21], showed that muscle 
cells from the adult mammalian heart are able to de-differentiate in vitro and 
acquire antigenic and morphologic features of CPCs. It is not clear however how 
frequently this phenomenon occurs in vivo and which functional properties these 
cardiomyocyte-derived cells have.  
Several groups have reported that a reactivation of the cell cycle is feasible by 
either removing cell cycle inhibitors (e.g., p27) or by over-expressing cell cycle 
activators [22], such as cyclinD1, cdk1, members of the E2F family, CDC5 and p38. 
Growth factors, such as neuregulin1 [23] and periostin [24], promote proliferation 
of fully differentiated cardiomyocytes even if their action seems to be limited to 
mononucleated cells (10-30% of total cardiomyocytes) and only a small percentage 
of these cells can actually complete karyochinesis. 
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Controlled layer or lineage transition (CLT) 
Controlled layer or lineage transitions (CLT), such as the epithelial-to-mesenchymal 
transition (EMT), are important biological processes through which polarized 
epithelial cells assume a mesenchymal phenotype, with enhanced migratory 
capacity, invasiveness, elevated resistance to apoptosis and a greatly increased 
production of extracellular matrix components [25]. Upon reaching their 
destination, migrating mesenchymal cells usually undergo reverse EMT [26]. The 
development of the mouse heart involves four distinct CLT episodes [27], each 
generating a distinct set of cardiovascular progenitor cells that differentiate into 
the cellular components of the mature heart. The first EMT that gives rise to 
cardiovascular progenitor cells takes place during gastrulation, when epithelial cells 
of the epiblast begin to delaminate, adopt mesenchymal characteristics and 
migrate to form the mesoderm layer that occupies the space between the two 
outer epithelia of endoderm and ectoderm [28]. The timing and location of 
epithelial cell delamination within the primitive streak determines the destination 
of the migrating mesodermal/mesenchymal cells in the developing embryo and this 
specifies their subsequent fate [29]. Mesodermal cells in the lateral plate adjacent 
to the foregut differentiate into progenitor cells that express early cardiac 
regulatory genes, such as Nkx2.5, Mef2c and Gata4 [30, 31]. Early cardioblasts are 
divided into two types representing the primary and secondary cardiac fields [32]. 
The cardiac stem cells of the primary field form the original heart tube that 
surrounds the endocardial vascular layer, contributing mainly to the future left 
ventricle; the secondary field cells then migrate and wrap around the primitive 
heart and contribute to the formation of the atria, the right ventricle and part or 
most, of the left ventricle [32, 33].  
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The  second mesenchymal transformation that shapes the heart takes place when a 
subpopulation of endocardial cells (the endothelial cells of the original inner cardiac 
tube) in the atrioventricular canal area undergo endothelial-to-mesenchymal 
transition (EndMT), migrate into the adjacent cardiac jelly and build the endocardial 
cushions that develop into the heart valves [34, 35]. There is evidence that EndMT 
continues in the adult valves, supplying cells to maintain and repair the valvular 
leaflets [36].  
The third EMT occurs in the epithelium formed by the epicardial cells at the outer 
surface of the heart. Pre-epicardial tissue, which appears as a cauliflower structure 
from splachnopleuric mesoderm during development, attaches to the exterior 
surface of the heart and spreads out over the entire organ in a single epithelial cell 
layer called the epicardium [37]. Shortly thereafter, the epicardial epithelium 
undergoes EMT, generating a mesenchymal stem cell population named epicardial-
derived progenitor cells or EPDCs. EPDCs invade the cardiac tissue and differentiate 
into interstitial fibroblasts, perivascular fibroblasts and smooth muscle cells (SMCs) 
of the developing coronary blood vessels [11, 38]. Cell-lineage tracing experiments 
using Cre-recombinase technology show the potential contribution of epicardium 
to a small fraction of ventricular myocytes, suggesting a more substantial role of 
EPDCs in heart tissue formation than was thought previously [39, 40]. 
Transplantation of embryonic EPDCs improved cardiac function after myocardial 
infarction (MI) in mice, but the cells did not differentiate into cardiovascular cells 
[41].  
The fourth EMT takes place in the neural tube and generates the cardiac neural 
crest (NC) progenitor cells, between the cranial and trunk neural crest, that migrate 
to the heart and take part in the remodeling of the aortic arch arteries and the 
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septation of the common outflow tract into the aortic and pulmonary arteries [42, 
43]. Lineage-tracing experiments, using transgenic mice with gene markers that are 
under the control of NC-specific promoter elements or Cre-recombinase 
technology, suggest that NC cells also contribute to the conduction system and 
epicardium, but this remains controversial [44-47]. Recent reports show that 
nestin+ stem cells of NC origin reside in the adult heart and take part in de novo 
blood vessel formation and reparative fibrosis after ischemic injury [48].  
While the significance of EMT and EndMT in organogenesis is well supported, little 
is known about the contributions of these processes to repair and regeneration in 
adults [25]. Terminally differentiated epithelia have recently been shown to modify 
their phenotype in response to repair-associated or pathological stress, [49] and 
EMT seems to yield adult cells with stem cell characteristics [50, 51].Therefore, one 
could predict that, in line with their role during heart development, EMT and 
EndMT contribute to the pool of cardiovascular progenitor cells to maintain cardiac 
homeostasis.  
Besides the connection of mesenchymal transition to the emergence of stem cells, 
both EMT and EndMT are recognized as important mechanisms in the generation of 
the myofibroblasts that take part in fibrosis [52, 53]. Therefore, it is possible that 
EMT and EndMT contribute to both cardiac regeneration and fibrosis after injury. In 
the last few years a number of studies have provided supportive evidences for this 
notion. For example, EndMT in the adult mouse heart gives rise to myofibroblasts 
that migrate and produce scar tissue in mouse models of pressure overload and 
chronic allograft rejection, recapitulating pathways that take place during 
formation of the atrioventricular cushions in the embryonic heart [54]. Moreover, 
EMT is induced after injury in activated epicardial cells expressing stem cell 
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markers, which migrate to the infarct and contribute to both cardiac and vascular 
cell types [55]. These experiments suggest a function of epicardial cells that echoes 
their role in the regeneration of the adult zebrafish heart after partial resection 
[16]. Therefore, both endothelial and epicardial cells become activated after injury 
in response to specific signals (such as EGF, FGF-2, TGF-β and PDGF) giving rise to 
cardiac, vascular and myofibroblast/SMCs, similarly to their capacity during 
development. 
Recruitment of exogenous progenitors or stem cells 
Almost ten years ago, different groups reported the presence of stem cell-like cells 
in the adult myocardium that bear sex chromosomes or genetic markers of 
recipient origin in the case of heart transplants (sex-mismatched transplants)[56], 
or of the donor in the case of BM transplants [57]. These extra-cardiac CPCs may 
arise from sources that continuously feed the heart with undifferentiated cells and 
acquire their tissue-specific properties once in the cardiac niche. The extent of this 
phenomenon is debated. Quaini et al. report that within 4-28 days after 
allotransplantation, up to 30% of transplanted myocardium is regenerated by stem 
cells originating from the recipient [56], which were able to differentiate in new 
myocytes, as well as endothelial and SMCs [58]. On the other hand, reported 
negative results include the detection of infiltrating host cells comprising up to 
5.6% of the vascular SMCs, but none of the over 6000 cardiomyocytes surveyed in 
the donor heart [59] and low levels (0.02% to 1%) of cardiomyocyte chimerism 
within allografted human hearts [60]. Further complicating the picture, the validity 
of stem-cell plasticity as a mechanism for generating non-lymphohaematopoietic 
tissue has also been questioned [61] and some authors have suggested that the 
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apparent cardiac chimerism might be explained by previously overlooked cell fusion 
events [62]. 
It is conceivable that circulating mononuclear cells responsible for generating solid-
organ–specific cells are actually a group of non-lymphohaematopoietic organ-
specific stem cells which move between their own solid tissue and the peripheral 
blood [63]. Numerous reports show that in the heart, at least for endothelium [64] 
and myofibroblasts [53], this can in fact be the case. 
Endogenous reservoirs of progenitor or stem cells in the heart 
Surprisingly several populations of autologous cardiac stem cells have been 
identified in the past decade. It is not clear if these populations are related and 
which is their origin.  It is possible to speculate that they may be remnants of 
embryonic precursors, or they can derive from extra-cardiac sources as the BM. 
Experiments of conditional lineage tracing are undoubtedly required to understand 
the origin and identity of these CPCs populations and their behavior in physiological 
and pathological conditions[65]. In this way it would be possible to assess if these 
cells are actually recruited to the site of injury, if they can undergo proliferation and 
convert into cardiomyocytes. 
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Figure 1.3. Different populations of resident cardiac stem and progenitor cells isolated since 2002.  
So far autologous CPCs have been isolated with different protocols, based either on 
functional properties or surface markers expression: 
 Expression of cell-surface stemness markers (c-kit or Sca-1). 
Based on the expression of the stem cell factor receptor, Anversa et al [66]  
identified a small population of c-Kit+/lineage negative cells, located in small 
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clusters within atria and ventricles. These cells were described as clonogenic, 
multipotent, capable of self renewal and they were isolated from different species, 
including human hearts. Although the phenotype of c-kit+ differentiating cells 
remains immature in vitro, they appeared to regenerate cardiac tissue when 
injected in rat hearts after MI, giving rise to cardiomyocytes, smooth muscle and 
endothelial cells, with a significant functional improvement after 20 days. The initial 
enthusiasm aroused by these studies was partially reduced by the identification of 
c-kit+ cells in tissues of other solid organs. These cells supposedly leave the BM in 
small numbers to scavenge pathogenic molecules as part of the mechanisms to 
activate local innate immune responses [67]. Furthermore, by means of in situ 
detection, c-kit+ cells from bioptic samples of human heart have been recently 
reported to co-express markers of mast cells and to lack cardiac markers, such as 
Nkx2.5 and Isl1 [68]. A possible change in cellular phenotype during the culture 
time course needs to be taken under careful consideration to explain these 
conflicting results [69]. Using a transgenic mice expressing eGFP under the c-kit 
promoter, Tallini et al. [70] observed c-kit cells at different stages of differentiation 
in the embryonic heart, peaking at post-natal (PN) day 2; thereafter EGFP+ cells 
declined and where rarely detected in adult hearts. C-kit-eGFP+ cells isolated from 
PN 0-5 were able to differentiate in endothelial cells, SMCs and beating myocytes. 
Cryoablation in the adult heart resulted in increased expression of c-kit–eGFP, 
peaking after 7 days. C-kit expression occurred in endothelial and SMCs in the re-
vascularizing infarct area and in terminally differentiated cardiomyocytes in the 
border zone surrounding the infarct. Thus they suggested that in vivo c-kit 
expression is associated with neo-vascularization, but not with de novo myogenesis. 
They conclude that the increased c-kit expression in differentiated cardiomyocytes, 
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in the injury border zone, could rather be the result of c-kit re-expression in 
committed myocytes[71]. 
One year later Schneider and al. [72] reported the presence of a population of cells 
expressing the Stem Cell Antigen (Sca-1) in the non-myocyte fraction of the heart. 
These cells co-localize with vasculature and express CD31, but have a distinct 
phenotype from endothelial and hematopoietic stem cells: they are negative for 
CD45, CD34, flk1, ckit, VE-cadherin, vWF and express early cardiac markers, such as 
GATA4 and MEF2c, suggesting a possible commitment towards cardiac and 
endothelial lineages. The exposure to 5-azacytidine induces expression of Nkx2.5 
and cardiac sarcomeric proteins. The capability to adopt a cardiac muscle fate in 
embryogenesis was substantiated by blastocyst injection. When injected 
intravenously in infarcted mice they were able to home and differentiate in the 
peri-infarct area, despite a significant percentage of fusion with resident myocytes 
(50%). 
Matsuura et al [73] isolated similar Sca1+ cells from hearts of 12-week old mice. 
When treated with oxytocin, these cells expressed genes of cardiac transcription 
factors and contractile proteins and showed sarcomeric structure and spontaneous 
beating. They may be able to differentiate in different cell types when exposed to 
different environments; however Sca1+ cells multipotency has not been proven on 
the progeny of single cells. Recently [74] they demonstrated that the 
transplantation of sheets of clonally expanded Sca1+ cells ameliorates cardiac 
function after MI in mice. Clonal Sca1+ cells efficiently differentiated into 
cardiomyocytes and secreted cytokines, including soluble VCAM-1 (sVCAM-1), 
which induced migration of endothelial cells and CPCs and prevented 
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cardiomyocyte death from oxidative stress through activation of Akt, ERK and p38 
MAPK. 
The group of Doevendans [75] identified cardiomyocyte progenitor cells (CMPCs) in 
fetal and adult human hearts using an antibody against mouse Sca1. Human CMPCs 
are localized within the atria, atrioventricular region and epicardial layer and they 
can be induced to differentiate in vitro into cardiomyocytes and form 
spontaneously beating aggregates, after stimulation with 5-azacytidine. Recently 
[76] this group investigated the effect of intra-myocardial injection of human 
CMPCs or pre-differentiated CMPCs-derived cardiomyocytes (CM-CMPCs) in 
immunodeficient infarcted mice. The results were higher ejection fraction and 
reduced left ventricular remodeling up to 3 months after MI, when compared to 
controls. Both CMPCs and CM-CMPCs were able to generate new cardiac tissue 
consisting of human cardiomyocytes and blood vessels, excluding the need for in 
vitro pre-differentiation. 
 Expression of the islet-1 gene (isl1+ cells). 
Laugwitz et al. [77] reported that early after birth the mammalian heart harbors a 
rare subset of cells positive for the LIM homeodomain transcription factor islet-1 
(isl1), that disappears soon after the neonatal period. These cells are mostly found 
in the outflow tract, atria and right ventricle, suggesting that they could be 
remnants of the embryonic secondary heart field. Postnatal isl1+ murine cells can 
be expanded in vitro on mesenchymal feeder layers and they undergo terminal 
differentiation when co-cultured with neonatal cardiac cardiomyocytes, acquiring 
electromechanical properties similar to those of adult cardiomyocytes, thereby 
fulfilling the criteria for endogenous cardioblasts. Moreover their bona fide identity 
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as true CPCs comes from extensive and detailed genetic fate mapping studies in 
vitro and in vivo, providing strong evidences of their cardiac-specific multipotency 
[78, 79]. However these cells were isolated only from very young animals, including 
human neonatal specimens and the number of Isl1+ cells dramatically decreases 
over the first weeks of life. Furthermore it remains to be addressed if these cells are 
multipotent and able to engraft and regenerate the myocardium. 
 Expression of the stage-specific embryonic antigen (SSEA-1+ cells). 
Recently uncommitted cardiac precursor cells (UPCs) have been identified in the 
heart of adult rats through a typical embryonic antigen, SSEA-1, that is expressed 
early in heart development[80]. SSEA-1+ cells isolated from adult rats differ from 
neonatal cells because they do not express cardiac specific transcription factors 
(Nkx2.5, GATA4). This suggests that only uncommitted stem cells persist in the 
adult heart. Adult UPCs in co-culture with cardiac-derived mesenchymal cells can 
differentiate in mature cardiomyocytes, endothelial cells and SMCs through 
multiple stages, in which the cells co-express markers such as Oct4, Flk-1 or Sca-1 
together with SSEA-1. Then, once committed, they finally express cardiac 
transcription factors such as Nkx2.5, GATA4 and Isl-1. Beating colonies are obtained 
by culturing UPCs in differentiating media or in co-culture with neonatal 
cardiomyocytes. UPCs improved ventricular function when injected in infarcted 
hearts and SSEA-1+ cells are capable of forming new cardiomyocytes and 
endothelial cells in the infarct area [80]. 
 Ability to efflux Hoescht dye (Side Population). 
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As other solid organs, the heart presents a Side Population (SP) of cells 
characterized by the ability to efflux vital dyes, due to the expression of ATP-
binding cassette transporters, such as ABCG2 and MDR1. Abcg2-positive cells were 
identified during embryogenesis and they persist as a small pool in multiple organs 
[39]. Cardiac SP cells express stem cell markers, such as Sca1 and cKit and are 
CD34+, CD31-, CD45-. They are capable of proliferation and differentiation towards 
mesodermal derivatives: isolated SP cells can be induced to express cardiac specific 
genes in vitro when treated with agents such as oxitocyn or tricostatin A and they 
are able to proliferate and form hematopoietic colonies when plated into 
metylcellulose media. The cardiogenic potential is higher in cells expressing the 
Sca1+ and negative for the endothelial marker CD31. However the actual 
regenerative contribution of these cells in vivo is not clear [81].  
 Cells deriving from the epicardium 
Limana et al. [55] first demonstrated the presence of CPCs outside of the previously 
described “niche”, in the adult epicardium of both mouse and human. Authors 
identified two different populations of c-kit+ and CD34+ cells, which can express 
early and late cardiac transcription factors (Nkx2.5, GATA4) and acquire an 
endothelial phenotype in vitro.  Following MI, there is an increase in the absolute 
number and proliferation of epicardial c-kit+, which undergo EMT [82] and migrate 
in the subepicardium [82]. EMT represents the first step for the acquisition of 
mesenchymal phenotype and consequent migration from the subepicardial space 
to the myocardial wall [82] where they generate myocardial precursors and 
vascular cells. They also demonstrated that in presence of an intact pericardium, 
these c-kit+ cells reactivate the expression of three embryonic epicardial related 
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genes Tbx18, WT1, Raldh2, probably due to the release of important trophic factors 
in the pericardial cavity [83]. 
EPDCs can also be isolated from human adult atrial tissue. In culture they 
spontaneously undergo EMT and differentiate in SMCs thus retaining 
characteristics similar to their embryonic counterpart [84, 85]. Further these cells 
have the potential to positively modify the phenotype of co-cultured adult 
cardiomyocytes increasing their contractility [86]. Transplantation of human adult 
EPDCs in the infarcted mouse heart preserves LV function and attenuates 
ventricular remodeling at 6 weeks after injury, even if only few cells engrafted in 
the host tissue, mainly acquiring a smooth muscle phenotype [41]. Noteworthy co-
transplantation of adult EPDCs with CPCs does not result in differentiation of these 
latter in functional cardiomyocytes. The synergistic improvement of cardiac 
function can be explained by the activation of distinct paracrine pathways by the 
two different populations [87]. Thus the beneficial effect of these cells relies mostly 
on an indirect paracrine protection of the surviving tissue. Therefore transplanted 
EPDCs recapitulate only in part their role during embryonic development, i.e. the 
modulatory effect, but not their physical contribution [87]. 
 
Cardiospheres and CSps-derived cells 
In our lab it has been demonstrated for the first time that CPCs can be isolated 
directly from cardiac tissue through selection of spontaneous spherical clusters, 
termed CSps [88]. After few weeks of culture, a heterogeneous population of cells 
shed spontaneously from tissue fragments (fig2). Explant-derived-cells (EDCs) are 
collected by mild enzymatic digestion, plated on poly-D-lysine in presence of 
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growth factors and low serum and they generate 3D-clusters called Cardiospheres 
(CSps).  
 
 
Figure 1.4. Stages of Cardiospheres culture. A- Cells migrating out of human explants; B- EDCs after 
4 days of culture; C-floating CSps;  D- CSps-derived cells (CDCs) 
CSps are characterized by a core of undifferentiated c-kit+ cells and differentiating 
cells towards the periphery, expressing markers of mesenchymal, endothelial, 
smooth muscle and cardiac cells, such as CD105, myosin heavy chain (MHC), 
troponin I (TnI), connexin-43 (Cx43), smooth muscle actin (SMA) and Von 
WIllebrand factor (vWF) (fig.1.6) [88, 89]. Recent experiments on explants obtained 
after retrograde perfusion in the absence of hematological cells (CD45−, lin−) 
disprove the notion that blood-derived elements figure prominently in the 
generation of CPCs from cardiac biopsies; furthermore c-kit+ cells appear to be 
negative for the mast cell marker AA4 [89] (fig.1.5). However in defined 
pathological conditions [90], as in mice depleted of the endogenous stem cell 
reservoir by irradiation and transplanted with BM before inducing MI, it has been 
shown that BM-derived cells can contribute to replenish the cardiac stem cell 
niches and participate to CSps formation. 
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In order to increase cellular yield, CSps can be expanded in monolayer on a 
fibronectin-coating as CSp-derived cells (CDCs), which retain the capability to form 
secondary CSps when re-plated in the previous conditions [91]. The vast majority of 
this heterogeneous population is CD105+ and significant subpopulations are CD90+, 
cKit+, CD34+ and CD31+. CDCs are also MDR1-, CD133- and CD45- and negative for a 
wide cocktail of blood lineage markers, resembling overall a mixture of CPCs and 
mesenchymal supporting cells (fig. 1.7).  
Both CSps and CDCs have been proved to significantly improve cardiac function in 
treated animals [91]. In a porcine pre-clinical model of post-infarct left ventricular 
dysfunction intracoronary delivery of CDCs has been shown to result in formation 
of new cardiac tissue, to reduce relative infarct size, to attenuate adverse 
remodeling and to improve hemodynamics [92]. The evidence of efficacy of this 
study, without obvious safety concerns at 8 weeks of follow-up, offered the 
fundamental background for human studies in patients after MI and in chronic 
ischemic cardiomyopathy. At present CDCs are under evaluation in the ongoing 
CADUCEUS clinical trial for autologous cell therapy (see www.clinicaltrials.gov for 
details). 
However CSps seem to have an enhanced functional potency for myocardial 
regeneration, compared to CDCs grown in monolayers, probably because the 3D 
structure closely resembles the tissue “niche”, in terms of interaction among 
different cell types and the matrix. Recently a study has been conducted comparing 
CSps, CDCs and cells deriving from CSps dissociation [93] (fig. 1.8-1.10). When 
implanted in the infarct border zone in a mouse model of acute MI, CSps exerted 
greater benefits compared to monolayer-cultured CDCs or dissociated CSps. All cell-
treated mice exhibited a reduced LV remodeling, but those treated with CSps 
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showed a net increase in LVEF which corresponded to thicker LV walls and smaller 
infarcts (fig.1.9). Analysis by PCR array, qPCR and immunostaining showed that 
culturing cells as CSps augments the expression of stemness markers as c-kit, SOX2, 
Nanog and stem cell-relevant factors as IGF-1 and Tert, while proliferation is 
inhibited compared to CDCs (fig 1.8). This may be related to the recapitulation of a 
stem cell niche microenvironment and HDAC-mediated epigenetic modifications. 
Many extracellular matrix (ECM) components and adhesion molecules, including 
lamin-β, integrin α2, E-selectin were also up-regulated and CSps resulted much 
more resistant to oxidative stress than monolayer-cultured cells (fig 1.8-1.9). These 
features are expected to favor the engraftment of stem cells after implantation in 
the damaged heart, explaining at least in part the greater functional benefit 
deriving from CSps. Therefore while CDCs can be easily expanded to significant 
number for clinical application, the 3D structure provides a protective 
microenviroment, improving cell engraftment and regeneration. 
 
 
Figure.1.5 Flow cytometry analysis of the first outgrowth collection from human and rat cardiac 
tissue [89]. 
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Figure 1.6 Confocal images of immunofluorescence characterization of human CSps [89]. 
 
Figure 1.7 CDCs phenotypic characterization by FACS. [91]
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Figure 1.8. Growth, proliferation and recapitulation of stem cell niche-like microenvironment of 
cells under CSp culture condition [93] 
 
Figure 1.9 PCR array analysis of the gene expression in CSps versus cells grown in mononalyer: 
stem cells relevant genes; ECM relevant genes [93] 
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Figure 1.10 A: Higher resistance to apoptosis of CSps vs cells in monolayer; B-D: higher rate of cell 
engraftment of CSps compared to cells in monolayer results in a greater functional benefit in vivo.
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Opposed from predicted single-marker selection criteria, the main advantage of 
this isolation method is the exploitation of the intrinsic functional property of the 
cells to spread out of the tissue and grow in three-dimensional structures, 
representing a more physiological culture condition compared to monolayers, 
where natural spatial cellular connections cannot be promoted. 
The single-marker and the function-based selection approaches have been 
combined by several groups and used to obtain regenerating cells from primary 
cultures of human cardiac or muscle biopsies, subsequently sorted for specific 
antigens. The sca-1 positive cardiomyocyte progenitor cells (CMPCs) obtained by 
Doevendans et al. [76] are an example of this combined procedure, as well as CSp 
derived Lin–/c-kit+ progenitor cells [94]. 
Interestingly, in our experience, [95] when CDCs were sorted for c-kit and injected 
in a mouse model of acute MI, the functional improvement was significantly lower 
than that of the whole population, suggesting that cooperative and synergistic 
effects among multiple cell types in the CDC pool play an important role on the 
overall beneficial outcome. Apart from the c-kit positive stem-like cells, other cell 
types expressing mesenchymal markers might also have a feeder-layer role, 
allowing the activation of multiple mechanisms for cardiac repair beyond myocyte 
formation (paracrine pro-survival effects, angiogenesis, mobilization of endogenous 
CPCs). 
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Scope of the dissertation 
 
Despite several populations of progenitor cells being identified in adult heart, these 
cells are clearly not sufficient to provide a significant regeneration of the 
myocardial tissue. Transplantation in infarcted hearts of progenitor cells expanded 
ex vivo has shown limited and conflicting results. Beneficial effects observed so far 
are mainly due to the release of paracrine factors. Just a small percentage of cells 
are able to survive and to engraft long-term in the host tissue. Furthermore the 
hostile inflammatory and ischemic environment may promote the differentiation 
toward a fibrogenic/vasculogenic lineage more than a cardiogenic one.  
In this regard, a better understanding of the origin of the employed progenitor cells 
population is required to control their differentiative fate in vivo and enhance their 
therapeutic effect. 
The main aim of my work was to gain insight on the origin and biological meaning 
of CSp-forming cells. First, using transgenic mice we evaluated the eventual 
contribution of pre-existing differentiated or de-differentiating cardiomyocytes to 
CSps formation. 
Secondly, after observing the significant role of CSp-forming cells in supporting 
proliferation and cardiogenesis in mouse embryonic stem cells (ESCs), we 
investigated the potential contribution of epicardial/epicardial-derived cells by 
means of lineage tracing and gene expression analysis. 
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Project I: Contribution of de-differentiating 
cardiomyocytes to Cardiospheres formation 
Introduction 
As mentioned above, cardiomyocyte de-differentiation and proliferation has been 
proven to be one of the main mechanisms accounting for the regenerative capacity 
of lower vertebrates such as zebrafish and newts [14, 15]. Several groups have 
reported that in particular conditions mammalian adult cardiomyocytes can be 
induced to re-enter the cell cycle and proliferate [22, 24]; furthermore a recent 
study [21] showed that muscle cells from the adult mammalian heart are able to 
de-differentiate in vitro and acquire antigenic and morphologic features of CPCs. 
In order to assess the role of cardiomyocytes in cardiac explants culture, we used 
three different transgenic mice strains expressing the recombinase Cre under 
cardiac specific promoters (MLC2v, TnT, Myh6), with a reporter locus included 
between two LoxP sites (Rosa26 flox or RBPj flox).  
Cre is a tyrosine recombinase from the bacteriophage P1 [96], which mediates 
recombinations of DNA molecules between two specific sites called LoxP (locus of 
X-over P1). LoxP sites consists of just 34bp. Cre specifically recognize and binds the 
Recombinase Binding Elements (RBE) , two 13bp sequences arranged as inverted 
repeats surrounding a central 8bp crossover region. The central 8bp are 
asymmetric with respect to sequence and define the directionality of the site [97].  
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Figure 2.1. LoxP sequence. 
Cre can recombine essentially any DNA substrate which contains LoxP sites, with no 
requirements for accessory proteins or specific substrate topology [98]. The 
simplicity of the Cre-loxP system has lead to its widespread use for both in vitro and 
in vivo genetic manipulation. This system, in fact, allows the creation of conditional 
mutant animal models where the inactivation of the target gene or the activation of 
the reporter locus is limited to a specific cell type or tissue. Conditional mutant 
mice are obtained by crossing a “floxed” strain, in which the locus of interest is 
modified by the insertion of two loxP sites, with a transgenic line expressing the 
recombinase Cre under a specific promoter or inserted into a particular locus in 
order to achieve a tissue-specific expression [24].  
In our case the expression of Cre under cardiac specific promoters would lead to 
the removal of a stop codon in the Rosa26 flox locus, with selective expression of β-
galactosidase in cardiomyocytes. The Rosa26 lacZ-loxP reporter strain contains a 
Cre-dependent, loxP-inactivated lacZ cDNA cassette targeted within the 
ubiquitously expressed Rosa26 locus [99, 100] (Figure 2A). Cre-mediated 
recombination of this allele deletes neomycin and a series of polyadenylation 
sequences, resulting in the juxtaposition of a splice acceptor site and the lacZ cDNA 
[101]. One of the strain we used presented also another “floxed” locus, RBPj flox 
[102] in heterozygosis, mainly to have a different reporter of recombination 
(detectable by PCR) than for its biological meaning. 
 35 
 
Figure 2.2 Targeting Rosa26 locus. [101] 
 
 
Figure 2.3 Targeting RBPj locus. [102]. 
Since it was our interest to be able to distinguish between pre-existing 
cardiomyocytes and de novo differentiating one, we took advantage of another 
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strain of transgenic mice Myh6-MerCreMer/Rosa26flox [103], in which the 
recombinase Cre fused with two Mer sequences, is subcloned downstream of  α-
MHC 5.5-kb cardiac-specific promoter. 
 
 
Figure 2.4 cDNA encoding the mutant estrogen receptor ligand-binding domain (Mer) flanking Cre 
recombinase (Cre) subcloned downstream of the αMHC 5.5-kb cardiac-specific promoter [103]. 
Mer is a mutant form of the estrogen receptor ligand-binding domain. The estrogen 
receptor is a hormone-activated transcription factor that is usually sequestered by 
heat-shock proteins in absence of the ligand. In presence of 17β-estradiol, the 
estrogen receptor is released, allowing participation in transcriptional regulatory 
complexes. Since its initial description, the ligand-binding domain of the estrogen 
receptor (amino acids 281 to 599) has been extensively used as a strategy for 
fusion-proteins sequestration within mammalian cells [103]. More recently, a 
mutation in the estrogen receptor at amino acid 525 (glycine to arginine) was 
described that rendered it insensitive to the endogenous 17β-estradiol, but 
sensitive to the estrogen antagonist tamoxifen [93]. The use of this mutant 
estrogen receptor (Mer) domain in fusion-protein strategies permits estrogen-
insensitive but tamoxifen-inducible activity within mammalian cells. In particular 
the Cre recombinase fused to two Mer sequences is inactive and sequestered in the 
cytosol. After a pulse with Tamoxifen activated Cre can translocate into the nucleus 
and recombine target floxed sites, activating the expression of the reporter LacZ in 
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all the αMHC-expressing cells in a time and space specific manner. In this way, only 
the cells that were differentiated at the time of tamoxifen treatment will be 
irreversibly labeled by LacZ expression and we could distinguish in culture between 
three different conditions: 
αMHC+ ßgal+  
Pre-existing differentiated 
cells   
αMHC+ ßgal-  de novo differentiation  
αMHC- ßgal+  
de-differentiation? 
transdifferentiation  
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Material and Methods 
Mice 
All experiments were conducted in accordance with the Guide for the Use and Care 
of Laboratory Animals and approved by the Institutional Animal Care and Use 
Committee. 
C57bl wild type and three strains of transgenic mice were used: TnT-Cre x Rosa26 
flox/+; MLC2v-Cre x Rosa26 flox/flox(+) x RBPjk flox/+; Myh6-MerCreMer x Rosa 
(flox/+) x RBPj (flox/+). All mice were provided by Doc. Mark Mercola Burnham 
Institute for Medical Research San Diego (CA). 
Genotyping  
For the genotyping of adult mice we used genomic DNA extracted from the tail tip. 
For newborns, we stained the upper part of the heart in X-galactosidase solution in 
order to know the genotype before starting the tissue culture and we confirmed 
the results by PCR on the genomic DNA extracted from the same cardiac tissue or 
from toes. Genomic DNA extracted from other tissues (skin, brain, lung and skeletal 
muscles) was used as a control to detect aspecific recombination.  
 
Genotyping primers 
Cre fw GCC TGC ATT ACC GGT CGA TGC AAC GA 
650bp 
Cre rv GTG GCA GAT GGC GCG GCA ACA CCA TT 
CreER fw ATA CCG GAG ATC ATG CAA GC 300bp 
 39 
CreER rv AGG TGG ACC TGA TCA TGG AG 
Rosa 523 GGA GCG GGA GAA ATG GAT ATG Tan 55°C 
wt 600bp 
Rosa flox 325bp 
Rosa 26F2 AAAGTCGCTCTGAGTTGTTAT 
Rosa 1295 GCGAAGAGTTTGTCCTCAACC 
RBPj F ATA ATT TGC CAA GCC AAA GC wt 110bp 
flox 250bp RBPj R TAA CTG TCT GGG ACC GAA GG 
 
Primers to detect deletion 
RBPj7s CCA AGC CAA AGC CCC TTT CT Tan 64°C 
wt 110bp 
flox 250bp 
del 480bp 
RBPj8as CCG AAG GCG ATT GAA CAG TG 
vRBPjre2a GCA GGC AAC AAT TGA GTG TG 
RosaLacz Fw TGC CCC CTC TTC CCC TCG TG 
350bp 
RosaLacz Rv ACG CCA GGG TTT TCC CAG TCA 
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DNA extraction:  
Genomic DNA from tissue has been isolated as previously described 
(http://web.mit.edu/jacks-lab/protocols/DNA_Isolation_tables.html). Briefly 
samples were incubated overnight at 56 °C in digestion buffer (10mM Tris pH 8.0, 
100mM NaCl, 10mM EDTA pH 8.0, 0.5% SDS in distilled water), to which we added 
Proteinase K (Sigma-Aldrich) at a final concentration of 0.4mg/ml. Genomic DNA 
was then purified and precipitated through a series of centrifugation steps with 6M 
NaCl and Isopropanol and finally resuspended in sterile water. For cells and 
embryos we used the Quick” Embryo Genotyping Protocol from Pfaff laboratory 
http://pingu.salk.edu/~pfaff/protocols%20and%20solns/geno.html. In this case the 
lysis buffer was made of 50 mM KCl, 10 mM Tris pH 8.3, 2 mM MgCl2, 0.1 mg/ml 
gelatin, 0.45% NP-40, 0.45% Tween-20, 0.1 mg/ml Proteinase K. Samples were 
incubated one hour or overnight (depending on the amount of material) in 500ul of 
buffer, then they were boiled for 10 minutes and 1ul was used in PCR. 
X-gal staining: 
X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside Invitrogen), was resupended in 
N,N-Dimethylformamide to obtain a 50x stock. X-Gal stock was diluted to a final 
concentration of 1mg/ml in staining solution made of: K3Fe(CN)6 20mM,  
K4Fe(CN)6*3H2O 20mM, MgCl2*3H2O 2mM, 0.01% DOC (Na salt), 0.02% NP40 in 
PBS.  
Staining of intact tissue (whole mounts). Hearts were fixed in 4% paraformaldehyde 
on ice for 20 minutes, rinsed twice in PBS, once in staining solution and left in X-Gal 
solution at 37°C for at least one hour. 
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Staining on cells and explants. For fixation we used 2% paraformaldehyde 0.2% 
gluteraldehyde for 5 minutes at 4°C. 
As a positive control for X-gal staining human embryonic fibroblasts were 
transfected with an Adenovirus expressing LacZ. 
Tamoxifen treatments: 
On cells and explants: 4-OH Tamoxifen (Sigma) resuspended in ethanol was added 
to the culture. Three different concentrations were tested 500nM, 1uM and 2uM 
for 2 to 4 days. The LacZ expression was analyzed after 1, 2 or 14 days from the 
treatment. We used a beta-pancreatic cell line MerCreMer- Rosa flox, kindly 
provided by Doc. Fred Levine’s lab, as a positive control. 
In vivo administration: 50mg Tamoxifen free base (Sigma)[103] or 4OH-tamoxifen 
(Sigma) [7]were dissolved in 500ul EtOH 100%, then 9.5ml of Corn Oil (Sigma) were 
added and the emulsion was sonicated to have a homogeneous solution. 100ul 
(0.5mg tam) were injected daily intraperitoneally in adult mice (20mg/kgBW/day) 
for 15 days [7], instead of 5 days as previously described [103], because it was 
shown to be insufficient[104] for a significant recombination in adult hearts.  
Other mice were treated with 80mg/kg BW of TAM administrated by oral gavage 
for 7 days. This treatment has been previously shown to be well tolerated and 
effective, even though causing a marked dilated cardiomyopathy, with a peak 3 
days after the treatment, but completely reversible after 21 days [104]. 
The control group consisted of Myh6-MerCreMer x Rosa26flox/+ mice not treated 
with tamoxifen and Myh6-MerCreMer x Rosa26+/+. 
Evaluation of the efficiency of recombination 
The upper part of the hearts was fixed with a solution of 2% paraformaldehyde, 
0.2% gluteraldheyde, 0.02% NP-40, 0.01% NaDC in PBS, for 3 to 4 hours at 4°C. 
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Afterwards the tissue was transferred in a 30% sucrose solution overnight, 
embedded in gelatin 7.5%-sucrose 15% on dry ice and we made 25μm cryosections. 
Those sections were fixed with PFA 4% for 15 minutes, covered in x-gal staining 
solution and left overnight at 37°C. After washing repeatedly in PBS, nuclei were 
counter-stained with “Nuclear fast Red” (Vector Laboratories), according to the 
manufacturer’s instructions. After dehydration, slides were mounted with 
Permount (Fisher Scientific). 
The percentage of recombinant lacZ-positive cells was quantified using the NIH 
Image Progessing and Analysis Software ImageJ. 
The deletion of RBPj locus was evaluated by PCR. PCR products were obtained by 
loading the same amount of genomic DNA on a 1.5% agarose gel; the intensity of 
the band was quantified with ImageJ software. 
Explants and Cell culture 
Isolated adult mouse hearts (excluding atria and the upper part of the ventricles) 
were diced into small tissue pieces 1 to 2 mm3 in size, washed with Ca2+-Mg2+-free 
phosphate-buffered solution (PBS) (Gibco) and digested for 5 minutes at 37°C with 
0.05% trypsin-EDTA solution (Gibco). The remaining tissue fragments were washed 
with complete explants medium (CEM) (Iscove’s Modified Dulbecco’s Medium 
(IMDM) supplemented with 20% fetal calf serum, 100U/mL penicillin G, 100μg/mL 
streptomycin, 2mmol/L L-glutamine and 0.1mmol/L 2-mercaptoethanol), 
transferred onto petri dishes coated with fibronectin (25μg/mL, BD Biosciences or 
Gibco) and cultured as explants in CEM at 37°C and 5% CO2.  
Part of the explants was cultured on coverglass or in 4-well chamber-slides, in order 
to have samples to stain before each cell-harvesting (passage). Explant-derived cells 
(EDCs) were harvested three times at intervals of one week, starting after 7days 
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(newborn mice) or 10 to 14 days (adult mice) from the beginning of the culture. At 
each passage, cells were collected by pooling two washes with Ca 2+-Mg2+-free PBS, 
one wash with 0.53mmol/L EDTA (Versene, Invitrogen) (1 to 2 minutes) and one 
wash with 0.05g/L trypsin and 0.53mmol/L EDTA (Invitrogen) (2 to 3 minutes) at 
room temperature under visual control. 
 The obtained cells were seeded on poly-D-lysine (BD-Biosciences) coated multiwell 
plates (BD-Falcon or Corning) in CSps-medium (CSM): 35% IMDM and 65% 
DMEM/F-12 Mix, 3.5% FBS (Hyclone), 1% penicillin-streptomycin, 1% L-glutamine, 
0.1mM 2-mercaptoethanol, 1 unit/mL thrombin (Sigma), 2% B-27 (Invitrogen), 
40ng/mL bFGF, 15ng/mL EGF and 1ng/mL cardiotrophin-1 (Peprotech). The media 
was partially changed every second day. Part of the cells were plated on poly-D-
lysine coated coverglass or in 4 well chamber-slides, fixed and stained after 4 days. 
Cardiospheres were obtained after one week/ten days. They were collected by 
gently pipetting, pre-plated on fibronectin-coated coverglass or chamber slides for 
6-12 hours and then stained.  
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Figure 2.5 Experimental design. Explants, EDCs, CSps were used for DNA or RNA extraction and fixed 
at each step of the culture for stainings. 
Immunostainings  
Explants, CSps-forming cells and CSps were fixed with 4% paraformaldehyde (4°C, 
10 minutes), rinsed twice with Ca2+-Mg2+-free PBS and permeabilized (0.2% Triton 
X-100 and 1% BSA). Non-specific antibody-binding sites were blocked with 10% 
goat or horse serum (according to host species in which the secondary antibody 
was generated), prior to incubation with primary antibodies. To detect cardiac 
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differentiation we used a mouse anti human and mouse α-actinin antibody (Sigma 
Aldrich) and mouse anti-mouse light meromyosin antibody (MF20 - Developmental 
Studies Hybridoma Bank), both tested on beating mouse embryoid bodies (EBs) as 
positive control and non beating Cripto-/- EBs as negative control. As endothelial 
markers anti-Tie2 (Santa Cruz) and anti-von Willebrand Factor vWF (Chemicon) 
antibodies were used. To detect cell proliferation we used rabbit anti-ki67 (Novus) 
and anti-phospho histone 3 H3P (Upstate). After washing in PBS containing 0.2% 
Triton X-100 and 1% BSA, cells were incubated with secondary antibodies: donkey 
anti-mouse Cy3 antibody (Jackson ImmunoResearch) or Alexa goat anti-rabbit 546, 
Alexa goat anti-mouse or goat anti-rabbit 488 (Invitrogen). To detect ki67 on cells 
previously stained with x-gal, we used a secondary antibody, goat anti-rabbit HRP-
conjugated (Promega), thus we quenched endogenous peroxidase activity by 
treating our samples with 0.5% peroxidase for 5 minutes and color reaction was 
developed using diaminobenzidine chromogen (DAB) solution (Vector Lab). Cells 
were than counterstained with hematoxylin. Vectashield (Vector Lab) or 
Ultramount (DAKO) were used as mounting media. 
Microscopy 
Images of whole mount stainings and x-gal stained explants were taken with the 
Stereoscopic microscope NIKON SMZ 1500. Images of cells and explants in culture 
were acquired with an Olympus Ix7l inverted microscope. For slides we used the 
Epifluorescent Zeiss Axioplan. Confocal microscopy was performed with a Leica TCS 
DMIRE 2 (LCS lite software Leica). No significant fluorescent signal was detectable 
with any of the secondary antibodies alone. 
Real-Time quantitative RT-PCR analysis 
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Total RNA was extracted using TRIZOL® Reagent (Invitrogen) according to the 
manufacturer’s protocol. One microgram of total RNA was used to synthesize first-
strand cDNA with random primers, using the the QuantiTect Reverse Transcription 
kit (Qiagen). Quantification of gene transcripts was carried out by real-time 
quantitative RT-PCR. Primers were tested and we obtained calibrations curves on 
serial dilutions of the positive control sample. Gene expression for each sample was 
normalized to the housekeeping gene GAPDH and normalized to the control (heart 
tissue for αMHC). Real-time PCR was performed with Sybr Green I Mastermix 
(Roche), using a LightCycler ® 2.0 Real-Time PCR System (Roche). Each reaction was 
run in triplicate and contained 2 μl of cDNA template along with 500nM primers in 
a final reaction volume of 20μl. Cycling parameters were:  95°C for 8’ (to activate 
DNA polymerase), then 40-45 cycles at 95°C for 3’, 60°C for 5’ and 72°C for 10’. 
Melting curves were performed with LightCycler software version 4.05 (Roche) to 
ensure only a single product was amplified. As negative controls, reactions were 
prepared without any template. 
 
RT-PCR Primers 
mGAPDH fw AAT GGA TAC GGC TAC AGC 
Tan 60 
mGAPDH rw GTG CAG CGA ACT TTA TTG 
mαMHC fw CAT GCC AAT GAC GAC CT 
Tan 60 
mαMHC rw CCT ACA CTC CTG TAC TGC C 
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Results  
TnT-Cre x Rosa 26 flox/+  
 
 
Figure 2.6. Expression of the Cre recombinase in TnT-Cre mice is not specific for cardiomyocytes.  
One of the mouse strain we used to trace cardiomyocytes in vitro, expressed the 
Cre recombinase under the TnT promoter, activating the reporter locus Rosa26flox 
 48 
in positive cells. The upper part of the hearts was used for x-gal staining in toto. 
Most of the EDCs were positive but cells from this strain did not form CSps. 
Furthermore staining on brain, on tibial muscles, on cardiac cryosections and co-
staining on EDCs showed that this reporter was not specific for cardiomyocytes, but 
it was also expressed in SMCs and skeletal muscle. 
MLC2v-Cre x Rosa 26 flox/+ xRBPj flox/+ 
Mice expressing the Cre recombinase under the myosin light chain 2v promoter 
[105] were bred with a reporter strain presenting two floxed loci, Rosa26 and RBPj 
in heterozygosis. MLC2v expression is restricted to ventricles at the earliest stages 
of ventricular chamber specification. Mice that present the knock-in with Cre in just 
one allele display no morphogenic defects and express normal levels of MLC2v. In a 
previous work [105] it has been shown that almost 80% of ventricular 
cardiomyocytes in postnatal heart had undergone recombination. Previous 
observations in our lab confirmed that the recombination occurs specifically in 
ventricular cardiomyocytes. In fact real time PCR for RBPj on cardiomyocytes and 
fibroblasts deriving from mice heterozygous for RBPj flox, showed complete 
absence of the PCR product just in cardiomyocytes. From whole mount x-gal 
staining it was observed almost 100% of recombination in adult heart, but a lower 
percentage in newborns (fig.2.7). 
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Figure 2.7 Characterization of the MLC2v-Cre x Rosa 26 flox(+) x RBPj flox(+) strain. A- Primers to 
detect the RBPj flox locus deletion. B- qPCR showing that the deletion of RBPj is specific for 
cardiomyocytes in KO mice (ACM: dispersed adult cardiomyocytes, Fb: fibroblasts). C- x-gal staining 
to detect deletion of the Rosa26 flox: recombination was almost 100% in adult heart, but 
incomplete in newborns. 
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For our experiments, we used litters of 6-day-old mice. X-gal staining showed that 
the efficiency of recombination was low and variable among litters. Regarding the 
other reporter locus, we observed aspecific deletion in some litters probably due to 
random activation of Cre during gametogenesis. Since MLC2v and RBPj are on the 
same chromosome 5, Cre and deleted RBPj are inherited together. To exclude 
aspecific activation, we tested by PCR different tissues, including brain, lungs, skin 
and tail.  
 
 
Figure 2.8. Example of genotyping and x-gal staining on sections of 6-days old MLC2v-Cre x Rosa 
26 flox/+ x RBPj flox/+ mice. 
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Figure 2.9. Example of an experiment with 6-day-old MLC2v-Cre x Rosa 26 flox/+ x RBPj flox/+ 
mice. PCR to detect RBPj deletion and x-gal staining on pre-plating tissue, explants pre-P1 (7 days of 
culture), EDCs 4 days after being harvested, explants pre-P2 (14 days of culture). From a Cre
+
 and a 
Cre
- 
  mouse. 
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On average 30% of the RBPj flox allele resulted deleted in the cardiac tissue pre-
plating, in accordance with the expected percentage of cardiomyocytes in the adult 
heart [106].The percentage dropped to 17% in the explants after seven days in 
culture and no deletion band was detectable by PCR on genomic DNA extracted 
from EDCs, CSps and even from explants after 2 weeks (fig. 2.9). Very rare x-gal 
positive cells were detected among CSp-forming cells and they resulted negative to 
the proliferation markers ki67 after co-staining (fig.2.10). 
 
 
Figure 2.10. x-gal positive EDCs are not proliferating cells. A- LacZ positive EDCs. B-C co-staining for 
ki67 revealed with a HRP-conjugated secondary antibody. Counter-stain with hematoxylin. 
Magnification 20x and 10x. 
Thus, despite the limitations of this model, these preliminary observations suggest 
that pre-existing differentiated cardiomyocytes tend to die with time in culture and 
very rare contaminating cardiomyocytes can be detected in EDCs. 
Myh6-MerCreMer x Rosa 26 flox/+ 
As previously discussed, this mice strain consent a temporal regulation of the Cre 
recombinase expression. Only the differentiated cardiomyocytes present at the 
time of Tamoxifen pulse will be irreversibly marked. We tried the treatment on the 
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explants in vitro using three different concentrations. While efficient recombination 
was observed already at the lowest concentration on the pancreatic β-cell line we 
used as positive control, we could not detect LacZ-positive cells among CSp- 
forming cells and the treatment resulted toxic, as shown by the lower number of 
CSps obtained compared to controls. Hence we decided to treat adult 12-week-old 
mice in vivo. 
 
 
Figure 2.11 Efficiency of recombination in Myh6-MerCreMer x Rosa 26 flox/+ mice. X-gal staining 
on 25μm cryosections from mice treated with 20mg/kg TAM intraperitoneally for 14 days or with 80 
mg/kg TAM by oral gavage for 7 days. Syngeneic mice not treated with TAM were used as control. 
Among the different protocols adopted, the most efficient one resulted to be the 
administration of 20mg/kg BW of 4-OH-tamoxifen for 15 days and mice were 
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sacrificed after 2 weeks in order to give time for the accumulation of a significant 
amount of the reporter enzyme β-galactosidase. 
In these conditions we obtained an average recombination efficiency of 72% on 
three mice (fig.2.11). X-gal staining was dramatically reduced in the explants 
already after one week of culture, before the first passage.  
 
 
Figure 2.12 Myh6-MerCreMer x Rosa 26 flox/+ mice. X-gal staining in explants 1 day of culture 
No blue cells were detected among the CSps-forming cells, fixed and stained 4 days 
after being harvested. Single blue cell were rarely detected at the periphery of 
larger CSps (fig.2.13). 
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Figure 2.13 Myh6-MerCreMer x Rosa 26 flox/+ mice. X-gal stainings on explants, EDCs, CSps from 
different passages. Drastic reduction of x-gal expression in explants already after one week of 
culture; aspecific reactivation in some samples after 21days. 
In some samples, after 3 weeks in culture, there seemed to be a re-activation of 
LacZ expression even in control explants (i.e. from mice not treated with 
tamoxifen). Most likely it was an artifact due to senescence-associated beta-
galactosidase activity [107]. In fact, using specific primers to detect the deletion of 
the Rosa locus, we failed to detect bands in samples other than the explants after 
one day of culture, suggesting that pre-existing differentiating cardiomyocytes die 
with time in culture and that there is no significant contamination among EDCs, first 
collected after a week. Furthermore real time PCR for Myh6 showed that in the 
explants after 7days of culture (before the first passage) the expression is reduced 
by 10-4 folds, compared to the tissue and almost 10-5 folds after 2 weeks. In cells 
collected from the explants, after 4 days of culture in CSp-growth medium, the 
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expression of Myh6 is further reduced 10-2 folds relatively to the explants from 
which they derived and 10-6 folds from myocardial tissue, while it was not 
detectable in newly generated CSps (7days after plating the EDCs). 
 
 
Figure 2.14 PCR to detect the deletion of Rosa26 locus.  
 
Figure 2.15 qPCR for αMHC on cardiac tissue, explants, EDCs, CSps 
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Immunostainings for cardiac markers, such as αActinin and light meromyosin MF20, 
showed that CSps obtained from adult mice did not contain terminally 
differentiated cardiomyocytes with a fully differentiated sarcomeric structure 
(fig.2.17); and staining of explants after 6 days and 10 days of culture confirm that 
cardiomyomyocytes in the plated tissue die with the time in culture (fig.2.16). 
 
 
Figure 2.16. Immunostainings on  murine explants after 6 days and 10 days of culture. 
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Figure 2.17. Immunostainings for cardiac markers Mf20 and αActinin on CSps, not-beating-Cripto
-
 
mEBs, beating Myh6_mCherry mEBs (positive control), CSps with no primary antibody added 
(negative control). 
Discussion 
The first part of our results, obtained using this experimental strategy, lead us to 
the conclusion that most likely mature cardiomyocytes do not directly (as CSp-
forming EDCs) or indirectly (as de-differentiating cells) contribute to CSps 
generation. In fact, in 6-day-old MLC2v-Cre x Rosa 26 flox/+ xRBPj flox/+ mice we 
observed deletion of the RBPj reporter locus only in explants after 1 day in culture 
and after 7 days (despite a drastic reduction), while it was not detectable in EDCs or 
in explants after 2 weeks. Recombination of the Rosa locus resulted low and 
variable. Rare blue positive cells were observed among the EDCs which resulted 
negative to ki67 staining. 
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With Myh6-MerCreMer x Rosa 26 flox/+ 3-month-old mice we obtained a higher 
efficiency of recombination of the Rosa locus, corresponding to approximately 72%. 
No positive cells were detected among EDCs and rare blue spots were observed in 
larger CSps. Aspecific LacZ activity was detected in some samples after 21 days in 
culture, but by PCR delection of the Rosa locus was observed only in explants after 
one day of culture. Besides, the expression of αMHC was dramatically reduced in 
EDCs and not detectable in CSps and staining on explants at different time points 
confirmed that cardiomyocytes tend to die with time in culture. 
The main limitation to the use of a conditional transgenic mouse model for lineage 
tracing experiments is that the efficiency of recombination is not 100%, so the 
results may be under-estimated. This is because, while Cre is expressed in 
temporally and spatially graded patterns, activation of a Cre-dependent reporter is 
a binary readout in which only cells surpassing a Cre exposure-threshold become 
activated. The specific threshold depends on the Cre-dependent reporter and the 
cellular context. Thus lack of the Cre reporter activation must be interpreted 
carefully, because this does not exclude Cre expression at levels below the 
threshold required for reporter recombination [108]. 
However the combination of different techniques allowed us to exclude a 
significant contamination of pre-existing differentiated cardiomyocytes in EDCs and 
CSps, suggesting that, at least in our culture conditions, cardiomyocytes de-
differentiation is not a crucial factor in CSps formation. 
Similar results have been obtained by two other groups, on different animal models 
[89, 109].
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Project II: Role of epicardial/epicardial derived cells in CSps 
formation 
Introduction 
A potential source for endogenous CPCs has been recently identified in the 
epicardium, an epithelial layer lining the cardiac surface. For many years the 
epicardium was believed to be a derivative of the myocardium, an inert layer of 
cells with the basic role to protect the myocardial from external factors. Starting 
from 1969 [110], embryological studies showed a non-myocardial origin for the 
epicardial tissue. It mostly derives from the proepicardium, a transient organ 
located in the pericardial cavity which in mammalian arises from the mesothelium 
of the septum transversus and consists of finger-like protrusions with an outer 
lining of epithelial cells and a core of undifferentiated mesenchymal cells. Recent 
lineage tracing experiments have shown that the proepicardium derives from a 
common cardiac precursor pool of cells Nkx2.5+/Isl1+, that generates most of the 
cell types in the heart [111]. During the process of cardiac looping, proepicardial 
cells migrate, either as individual cells (in mammalian) or as sheets (in birds) and 
envelope the developing myocardium. This process is probably spatiotemporally 
regulated by the expression of adhesion molecules and ECM components on the 
myocardial surface [38]. Integrin α4β1, a cell adhesion receptor, is expressed on 
proepicardial cells as they migrate onto the surface of the heart. It binds to 
fibronectin a major component of the extracellular matrix and to VCAM-1 a 
member of the immunoglobulin family. It has been shown that in knockout mice 
ablation of the α4 subunit of integrin α4β1 [112], of VCAM-1 [113] or of Podoplain 
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(a mucin-like transmembrane glycoprotein) [114], impairs epicardial outgrowth and 
spreading on the myocardium, resulting in several abnormalities such as 
hypoplasia, defective atrio-ventricular (AV) valve development, incomplete intra-
ventricular septation and alteration of the coronary vasculature. Thus the correct 
formation of the epicardial layer is crucial for the normal development of the heart. 
This is because the epicardium is both a source of multipotent mesenchymal 
progenitors and of instructive soluble signals that stimulate coronary vessel 
development, as well as cardiomyocyte proliferation and differentiation. During 
development, some epicardial cells undergo an epithelial-to-mesenchymal 
transition (EMT) and delaminate from the epicardium to invade the subepicardial 
space, which consist of hydrated extracellular-matrix rich in proteins. Some of these 
epicardial-derived cells (EPDCs) remain as mesenchymal cells or form blood islands; 
others migrate further into the myocardium and endocardial cushions, where they 
differentiate into different cell types. A recent study showed that Wilms tumor-1 
(WT1) has a crucial role in regulating this process[115]. Wt1 is a zinc-finger protein 
involved in the normal development of several organs, such as kidney, gonads, 
spleen and heart. Wt1-mutant mice present coronary vascular defects, so in order 
to determine WT1 function in epicardial cells, conditional knockout Wt1-loxP/GFP x 
Gata5-Cre mice were used, in which the expression of Wt1 is selectively lost in 
epicardial cells. These mice died between E16.5-E18.5 for cardiovascular failure: 
Cre+ E16.5 embryos presented edema and accumulation of blood in the systemic 
veins; pericardial hemorrhage; coronary artheries did not form; the right ventricles 
of some mutant embryos had thinner free walls compared to control embryos. 
Despite all this, the epicardial layer was integer and, in fact, Cre+ hearts were lined with a 
GFP+ epithelium.  These epicardial cells presented a significantly reduced expression 
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of Snail (activator of EMT) and of Vimentin, while epithelial markers E-cadherin and 
cytokeratin were upregulated. Using a tamoxifen-inducible Wt1-knockout 
immortalized epicardial cell line (Cre+ CoMEECs), they observed that TAM 
treatment led to loss of Wt1 expression with a robust dose-dependent increase in 
E-cadherin expression, down-regulation of N-cadherin, α-SMA and Snai1 and 
reduced mobility. Similar changes were observed in ESCs obtained from Wt1 KO 
mice. While wild type ESCs expressed high levels of vimentin, α-SMA and Snail, but 
not E-cadherin, (indicating that these cells had undergone EMT), Wt1-KO ESCs 
presented high levels of E-cadherin, did not express mesenchymal markers, were 
unable to undergo EMT, their mobility was impaired and the generation of 
mesoderm precursors (hematopoietic, endothelial, cardiac) was compromised, but 
could be rescued by the expression of Snai1. Thus Wt1 controls EMT processes 
through direct regulation of the Snail transcription factor and E-cadherin. This 
function appears to be crucial for the generation of mesenchymal cardiovascular 
progenitor cells from the epicardium and during ESCs differentiation. Analysis of 
quail-chick chimeras and retroviral labelling experiments suggest a primitive 
epicardial origin for the mesenchymal cells of the subepicardial layer, the 
endothelium and the SMCs (SMCs) of the coronary vasculature, the perivascular 
and intermyocardial fibroblasts and some cells in the atrioventricular valves[38, 
116]. More recent studies in mouse, using the Cre-lox technique to examine the 
fate of Wt1+ [40] and Tbx18+ [39] epicardial cells, showed that Wt1/Tbx18 
descendants contribute to the coronary vessel SMCs and the fibroblasts of the 
myocardial interstitium. Unlike reports in chick, they found that in mice only a small 
population of coronary vascular endothelial cells is derived from the epicardium. 
Furthermore both papers suggest a contribution of epicardial cells to 
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cardiomyocyte formation; however, this suggestion is questionable, since 
expression of Tbx18 is not confined to the epicardium, but it is also found in 
cardiomyocytes of the interventricular septum and the left ventricle [117]. As 
mentioned before, there is evidence that epicardium-derived secreted molecules 
signal to the underlying myocardium, modulating both EPDC-derived coronary 
vascularization and ventricular development. In particular both retinoic acid (RA) 
and Erytropoietin (EPO) act in parallel to induce cardiac mitogen release from 
epicardial cells [118]. RA signaling in the epicardium up-regulates myocardial FGF2, 
thereby leading to cardiomyocyte proliferation. FGF9, FGF16 and FGF20 are also 
released from the epicardium and specific inactivation of their receptors FGFR-1 
and FGF-R2c in the myocardium leads to defects in cardiomyocytes development 
[119]. Even EPDCs are a source of paracrine signals for cardiomyocytes and 
intermyocardial fibroblasts, which are at least partly epicardially derived, promote 
cardiomyocyte proliferation during development [120]. On the other hand, 
myocardial tissue releases important factors to modulate epicardial functions. For 
example FGF1, FGF2 and 7 released from the myocardium increase the expression 
of FGFR-1 in the epicardium, triggering the activation of Hedgehog (HH) signaling 
which controls the expression of multiple angiogenic factors such as VEGFA, VEGFB, 
VEGFC and Angiopoietin-1, crucial for coronary vasculature development. 
Furthermore FGFR-1 overexpression promotes EMT from epicardium and its 
knowckdown impairs the ability of epicardial cells to invade the myocardium and 
contribute to intramural vasculature. Secretion of the Platelet Derived Growth 
Factor-B (PDGFB) by myocardium is important to stimulate EMT and promote 
expression of SMCs markers. In addition embryonic hearts express high level of 
angiopoietin-1 which binds the receptor Tie2 expressed in the epicardium and 
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endocardium and this interaction resulted essential for vasculature development 
and maintanance. Thymosin ß4 (Tmsb4), a 43-aminoacid G-actin-sequestering 
peptide, is expressed throughout development in myocardium and epicardium 
[121, 122]. This peptide is known to regulate actin cytoskeletal organization and it 
is required for several biological cell functions, including cell motility and 
organogenesis [123]. It has been shown that Tmsb4 stimulates cardiomyocyte 
migration in vitro and increases cardiac function while promoting the survival of 
cardiomyocytes in vivo [122]. Notably, coronary vasculature formation is impaired 
in cardiac specific Tmsb4-knockout mice, suggesting that the loss of secreted Tmsb4 
in these mice may result in altered paracrine signaling to the epicardium [121]. 
Finally, the addition of Tmsb4 to embryonic epicardial explants significantly 
increases the number of endothelial and SMCs and, under these culture conditions, 
endothelial cell differentiation can be further enhanced in the presence of FGF7 
and VEGF [121]. The synergistic action of Tmsb4 and VEGF is consistent with the 
VEGF downregulation observed in Tmsb4-knockout mouse heart [121]. In 
conclusion, a finely regulated interplay between epicardium and myocardium, 
mediated by release of paracrine factors, is essential for embryonic heart 
development. 
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Figura 3.1 Role of the epicardium during embryonic development (modified from [116]) 
Recent studies have shown that in certain conditions the adult epicardium can 
reactivate the embryonic gene expression program, suggesting that, apart from the 
mechanical function, it can contribute to repair processes as observed in zebrafish. 
For example, exposure to specific soluble factors such as Prokineticins and 
thymosin bβ4 has been clearly shown to modulate adult epicardial cells. 
Prokineticins are small secreted bioactive peptides, comprising two classes: 
prokineticin-1 and prokineticin-2. They exert their biological functions through 
activation of two G-protein-coupled receptors, PKR1 and PKR2, which have two 
opposite effects in the heart: PKR2 displays detrimental actions, leading to 
hypertrophic cardiomyopathy and vascular leakage [124], whereas PKR1 confers 
survival signaling in cardiac myocytes and reduces apoptotic cell death following 
hypoxia [125]. Mice overexpressing PKR1 in cardiomyocytes display an increased 
number of proliferating EPDCs, of coronary arterioles and a higher capillary density. 
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Notably, cardioblasts overexpressing PKR1, up-regulate prokineticin-2 which in turn 
enhanced, in vitro, both neonatal and adult EPDC differentiation into SMCs and 
endothelial cells. Prokineticin-2 actions are mediated by PKR1 expressed in EPDCs 
since prokineticin-2-induced proliferation and differentiation are reduced in the 
PKR1-null mutant EPDCs [126]. 
As we mentioned above Tmsb4 has an important role during cardiogenesis, 
particularly for coronary vasculature formation. It has been shown that systemic 
administration of Tmsb4 in infarcted mice preserves cardiac functions and 
decreases scar volume by two different mechanisms. On one side acting on Akt, 
Tmsb4 improves early cardiomyocytes survival, cardiomyocytes and endothelial 
cells migration [122].  On the other hand, [127] it induces an organ-wide epicardial 
thickening and the reactivation of the embryonic developmental program in adult 
epicardial cells, as indicated by: increase of blood vessel/epicardial substance (Bves) 
expressing cells (marker of epicardial cells or cells of epicardial origin in adult and 
embryonic tissues); elevated VEGF, Flk-1, TGF-β, FGFR-2, FGFR-4, FGF-17 and β-
Catenin expression; increase of Tbx-18 and Wt-1 positive myocardial progenitors 
also migrating in the myocardium and subepicardial space. The result is a significant 
increase in capillary outgrowth from the epicardium within the border zone and 
infarcted area [121, 127]. 
Besides, MI induces embryonic reprogramming of a subset of c-kit+ epicardial cells 
with reactivation of Raldh2, Tbx18 and Wt1, especially in the presence of an intact 
pericardium, suggesting an important role of soluble factors in the pericardial fluid 
[83]. Whether these mediators are secreted by epicardial or myocardial cells is not 
known. Most likely both compartments release important trophic factors. In 
particular insulin-like growth factor 1 (IGF-1), hepatocyte growth factor (HGF) and 
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high mobility group box 1 protein (HMGB1), were significantly increased in the 
pericardial fluid post MI (PFMI), compared to pericardial fluid of non ischemic 
patients.   
Previous studies in our laboratory [128] have shown that CSps and CDCs exert an 
important paracrine effect both in vitro and in vivo, releasing different cytokines 
and growth factors, in particular VEGF, HGF and IGF1. Furthermore direct co-
culture experiments conducted in collaboration with Doc. Mercola’s lab have 
shown that CSps forming cells are able to significantly increase cardiogenesis in 
mouse ESCs. For these experiments we used a line of CGR8 Myh6-eGFP cells. We 
seeded cells CSp-forming cells in dark mw384 and the following day, we plated on 
top of them single cells deriving from dispersion of EBs at day 4 of the 
differentiation protocol (Mesendoderm committed cells). We changed media after 
2 days adding FGF and serum 0.6% and after 4 days with serum free medium. After 
6days of co-cultures (day 10 of EBs differentiation) we could observe beating GFP 
positive EBs and the amount of cardiogenesis was quantified measuring the 
fluorescence intensity with IN Cell 1000 Analyzer™ (GE Healthcare). 
 
Figura 3.1 Images of co-culture of CGR8 Myh6-eGFP mESCs and CSp-forming cells. Left panel: 
bright field, Right panel: green channel (eGFP). 
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Thus given the trophic role of CSps and CDCs, which are able to substain 
cardiomyocytes proliferation and differentiation, we decided to evaluate the 
potential contribution of epicardium or epicardial derived cells in CSps formation. 
The eventual presence of this contribution would give an added value to CSps 
biological meaning, owing to the potential of epicardial cells to undergo epithelial-
to-mesenchymal transition (EMT), with important functional and clinical implication 
for the fate of transplanted cells. 
To this propose, we used transgenic cGATA5-Cre Rosa26flox mice. In this animal 
model the Cre recombinase is expressed under the control of a specific portion of 
chicken GATA5 promoter [129], which is selectively activated in proepicardium 
starting from E9.5; thereby all epicardial and epicardial derived cells will be LacZ 
positive in the adult heart [130]. Then we proceeded with a gene expression 
analysis on murine and human samples of epicardial markers (TBX18, WT1), 
epithelial/endothelial markers (E-cadherin, Ve-caherin, Tie2), mesenchymal 
markers (Vimentin, SMA) and a marker of EMT (Snail). 
Material and Methods 
Mice 
All experiments were conducted in accordance with the Guide for the Use and Care 
of Laboratory Animals and approved by the Institutional Animal Care and Use 
Committee. Two-month-old GATA5-Cre Rosa26flox mice were kindly provided by Dr 
Pilar Lozano’s lab. Gene expression analyses were conducted on CD1 wild type mice 
7-day-, 3-month-old or embryos E10.5. 
Explants and Cell culture 
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Mouse hearts and human biopsies from auricola of two patients (male 63 years old, 
female 62 years old) were cultivated as explants as described above(pag. 42).  
Briefly the myocardial tissue was triturated and enzymatically digested with 0.05% 
trypsin-EDTA solution (Gibco) before being plated on fibronectin coated petri 
dishes in CEM. After 7 days for mice, or about 20 days for human we harvested 
explant derived cells (EDCs) for the first time. EDCs were collected 2 or 3 more 
times from each explant culture, at intervals of a week. From each harvest 100000-
200000 cells were seeded on poli-D-lysine in CSps-medium (CSM) at a density of 
9000 cells/cm2 to obtain CSps. The remaining cells were washed in PBS without 
Ca+2/Mg+2, spinned down, resuspended in RNA later (Invitrogen) and stored at -
20°C before RNA extraction. CSps were obtained after 5 to 10 days. They were 
collected by gentle pipetting, leaving adherent cells behind, and centifugated at low 
speed to eliminate contaminating cells. Approximately 25% of the obtained CSps 
were expanded on fibronectin coated wells, while the rest were washed in PBS, 
spinned down and resuspended in RNA later. CDCs were collected at confluence 
after 4 days. Part of the cells (approximately 70000) were re-plated in CSM on poli-
D-lysine to obtain seconday CSps; the remaining ones were preserved in RNA later 
and stored at -20°C before RNA extraction. 
X-gal staining: 
X-gal stainings to detect epicardial or epicardial derived cells in cultures of hearts 
deriving from cGATA5-Cre Rosa26flox mice were conducted as described before 
(pag.40). Explants or CSps were fixed with 2% paraformaldehyde 0.2% 
gluteraldehyde for 5 minutes at 4°C. Afterwards the samples were rinsed twice in 
PBS and once in staining solution made of K3Fe(CN)6 20mM,  K4Fe(CN)6*3H2O 
20mM, MgCl2*3H2O 2mM, 0.01% DOC (Na salt), 0.02% NP40 in PBS.  Finally we 
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added X-gal, 5-bromo-4-chloro-3-indolyl-β-D-galactoside (Invitrogen), diluted to a 
final concentration of 1mg/ml in staining solution and we incubated the samples for 
at least one hour or overnight at 37°C for the staining to be developed. 
RNA extraction and cDNA synthesis 
Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen) which 
includes a guanidine-isothiocyanate lysis buffer and silica-membrane columns for 
purification. To extract total RNA from adult cardiac tissue, embryonic hearts and 
pieces of explants we used TRIZOL® Reagent (Invitrogen) according to the 
manufacturer’s protocol. Tissue samples were homogenized with Turrex, when 
necessary, and an additional centrifugation step was performed in order to remove 
the excessive extracellular material. One microgram of total RNA was used to 
synthesize first-strand cDNA with random primers, employing the QuantiTect 
Reverse Transcription kit (Qiagen). Quantification of gene transcripts was carried 
out by real-time quantitative RT-PCR.  
Real-Time quantitative RT-PCR analysis 
Real-time PCR was performed with SYBR Green I detection chemistry, utilizing the 
iQ SYBR Green Supermix (Biorad) on a MiniOpticon™ Two-Color Real-Time PCR 
Detection System with CFX Manager software (Biorad). Each primer pairs was 
tested on serial dilutions of a positive control sample with a gradient of 
temperature in order to obtain calibration curves and select the appropriate 
annealing temperature, according to efficiency and r2 values. For endothelial and 
mesenchymal markers we used murine or human heart tissue as positive control. 
For murine epithelial and epicardial markers we used cDNA deriving from 10.5E 
CD1 mice embryos. Human Cdh1 primers were tested on cDNA from MCF-7 cells, 
an E-cadherin-positive weakly invasive human breast carcinoma cell line (kindly 
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provided by Prof. Marchese, Dep. of Experimental Medicine, “Sapienza” University 
of Rome). Human Wt1 primers were tested on cDNA from the human 
erythromyeloblastoid leukemia cell line k562 [131] and primers for human TMSBX4 
were tested on cDNA from myeloma cells (kindly provided by Prof. Santoni, Dep. of 
Molecular Medicine, “Sapienza” University of Rome). Efficiency values in a range of 
100±10%, with r2>0.990, were accepted.  
Each reaction contained 1 μl of cDNA template along with 200nM primers in a final 
reaction volume of 25μl. The sequences and annealing temperatures of the primers 
used are shown in Table 1 and 2. Cycling parameters were: 95°C for 3 minutes (to 
activate DNA polymerase), then 40 cycles at 95°C for 10 seconds, 10 seconds at the 
chosen annealing temperature and 30 seconds at 72°C. Melting curves were 
performed using Bio-Rad CFX Manager software to ensure only a single product 
was amplified. As negative controls, reactions were prepared in which no cDNA 
template was included. 
Gene expression for each sample (e-Ct) was normalized to the expression level of 
the housekeeping gene GAPDH (e-Ct gene/e-Ct GAPDH). Data were plotted as: ratio 
between CSps expression/EDCs expression; average expression in EDCs, CSps, CDCs, 
IICSps; average expression in EDCs and CSps from different harvesting (P1 and P2). 
All results are presented as mean value ± standard deviation, unless specified. 
Significance of difference between any two groups was determined by two-sided 
Student t test. A final value of P<0.05 was considered significant.  
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Table 1. Murine PCR Primers 
Gene Sequences Length Tan Efficiency R2 
 
GAPDH  
NM_008084.2 
5’-CGTCCCGTAGACAAAATGGT-3’ 
5’-TTGATGGCAACAATCTCCAC- 3’ 110 56 98.7 0.996 
Cdh5/VeCad 
NM_009868.3 
5’-CGTGGTGGAAACACAAGATG-3’ 
5’-AGACGGGGAAGTTGTCATTG-3’ 98 56.5 101.9 0.999 
Chd1 PB 
NM_009864.2 
5’-CAAGGACAGCCTTCTTTTCG-3’ 
5’-TGGACTTCAGCGTCACTTTG-3’ 165 55 91.8 0.995 
Wt1[115] 
NM_144783.2 
5’-GCCTTCACCTTGCACTTCTC-3’ 
5’-GACCGTGCTGTATCCTTGGT-3’ 186 59 100.8 0.997 
Tbx18 PB 
NM_023814.4 
5’-GTACCTGGCTTGGCACGAC-3’ 
5’-GCATTGCTGGAAACATGCG-3’ 151 55 100.8 0.992 
Snai1[115] 
NM_011427.2 
 
5’-CGTGTGTGGAGTTCACCTTC-3’ 
5’-GGAGAGAGTCCCAGATGAGG-3’ 120 56 96 0.997 
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SMA 
NM_007392.2 
5’-CTGACAGAGGCACCACTGAAC-3’ 
5’-AGAGGCATAGAGGGACAGCA-3’ 
123 59 96.2 0.991 
TMSBX 
NM_021278.2 
5’-ATGTCTGACAAACCCGATATGGC-3’ 
5’-CCAGCTTGCTTCTCTTGTTCA-3’ 
124 60 105.2 0.993 
 
Table 2. Human PCR primers 
Gene Sequences Length Tan Efficiency R2 
 
GAPDH 
 NM_002046.3 
5’-ACAGTCAGCCGCATCTTC-3’ 
5’-GCCCAATACGACCAAATCC- 3’ 110 57 96 0.999 
Tie2 
NM_000495.3 
5’-GTCTCTGCTCTCCAGGATGG-3’ 
5’-TGGCAAATCCACTATCTTTGG-3’ 83 57 95.5 0.991 
Chd5  
NM_001795.3 
5’-CAACGGAACAGAAACATCCC-3’ 
5’-CTGCTGCTGCCACTGCT-3’ 134 56.5 92.6 0.99 
Cdh1 
NM_0004360.
3 
5’- CAGGAGTCATCAGTGTGGTCA -3’ 
5’- TGTGCTTAACCCCTCACCTT -3’ 104 58 94.9 0.995 
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Wt1 
NM_024425 
5’-GCCAGGATGTTTCCTAACGC-3’ 
5’-CGAAGGTGACCGTGCTGTAA-3’ 91 59 101.6 0.991 
Tbx18  
NM_00108050
8.1 
 
5’-GCCCCTGCTGACTATTCTGC-3’ 
5’-CTGCATGGATAAGCTGGTCTG-3’ 228 59 101.6 0.991 
Snai1 
NM_005985.2 
 
5’-AATCGGAAGCCTAACTACAGCG-3’ 
5’-GTCCCAGATGAGCATTGGC-3’ 147 60.4 97.7 0.995 
SMA 
NM_001613.2  
5’-ATGAAGATCCTGACTGAGCG-3’ 
5’-GCAGTGGCCATCTCATTTTC-3’ 
123 58 93 0.998 
Vimentin 
NM_003380.3 
5’-ACCCACTCAAAAAGGACACTTC-3’ 
5’-GGTCATCGTGATGCTGAGAA-3’ 
88 56 92 0.997 
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Results  
Staining of explants and CSps deriving from cGATA5-Cre x Rosa26flox adult mice 
revealed a large amount of LacZ-positive cells, suggesting a possible contribution of 
epicardial/epicardial-derived cells in CSps formation. The main limitation of this 
model is that the recombination cannot be modulated in a time-specific manner: 
Cre is expressed when the cGATA5 promoter becomes active in proepicardial cells 
at E9.5, therefore all cells deriving from those proepicardial precursors will be 
irreversibly labeled by LacZ expression, including epicardial cells, EPDCs, a subset of 
inter-myocardial fibroblasts and the SMCs of the coronary arteries. Previous studies 
have shown that in particular conditions adult epicardial cells can re-activate genes 
that are normally expressed during development such as WT1, Tbx18, Raldh2, with 
consequent EMT, which led to the generation of multipotent mesenchymal 
progenitor cells. To verify if this could happen even in our culture system, we 
analyzed by RT-PCR the expression of epicardial markers (TBX18, WT1), 
epithelial/endothelial markers (E-cadherin, Ve-cadherin, Tie2), mesenchymal 
markers (Vimentin, SMA) and a marker of EMT (Snail). 
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Figure 3.3 Characterization of cGATA5-Cre x Rosa26flox mice (modified from[130]). I) Whole-
mount staining and histological section of an E12 embryo showing Cre activity in the epicardium, 
pericardium and body wall. P) In postnatal hearts (postnatal day 3), LacZ activity is detected in the 
epicardium and subepicardial layers and in a subset of intermyocardial fibroblasts (Q) and in the 
smooth muscle of the coronary arteries (R). Note the absence of Cre activity in the coronary 
endothelium (R). Epi, epicardium; myo, myocardium; ivf, interventricular fibroblasts; cv, coronary 
vessel; sm, smooth muscle; en, endocardium. 
 
Figure 3.4 cGATA5-Cre x Rosa26flox mice. X-gal staining on explants pre-P1 (7 days of culture), 
pre-P2 (14 days),  pre-P3 (21 days),  pre-P4 (28days) and CSps. 
Preliminary data on cultures from 7-day-old CD1 mice showed a significant 
reactivation of TBX18 and WT1, increased expression of Cdh1 and Snail in CSps 
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compared to adult heart, explants and EDCs, while SMA appears to be reduced in 
CSps. Vimentin expression was not significantly different in CSps compared to EDCs, 
while Tmsb4 was more expressed with the time in culture (fig. 3.5-3.6).  
 
 
Figure 3.5 Gene expression analyses on murine samples. Expression of Wt-1, Tbx18, Snai1, Cdh1 
and SMA in: CSps versus adult heart; CSps vs explants; CSps vs EDCs; CSps versus E10.5 embryonic 
heart. 
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Figure 3.6 Real time PCR analyses on explants, EDCs and CSps from 7-day-old CD1 mice.  
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Subsequently, we analyzed gene expression in samples deriving from two human 
biopsies. In fig. 3.7 we plotted the average ratio of the expression in CSps compared 
to the EDCs from which they derived, calculated on 8-10 samples for each 
examined gene. Seven genes appear to be expressed in a significantly different 
manner in CSps compared to EDCs: endothelial markers (Tie2, Cdh5), Wt1 and Snail 
are upregulated, while Cdh1 and SMA are significantly downregulated. In fig. 3.8-
3.11 we represented for each gene the average values of expression in EDCs, CSps, 
CDCs, IICSps and the levels of expression in EDCs and CSps from different cellular 
harvests. From these graphs it is possible to infer that the expression of hWt1 is 
significantly higher in three dimensional structures (CSps and IICSps) compared to 
monolayer cells (EDCs and CDCs). In the same conditions SMA and Cdh1 expression 
is significantly reduced. The expression of Cdh5, Tie2 and Snail is increased in CSps, 
CDCs, IICSps compared to EDCs, especially in the 3D structures. Instead levels of 
Vimentin expression are not significantly different among the four cell populations 
examined. The main discrepancy with the results observed in mice seems to be the 
Cdh1 expression, upregulated in murine CSps and significantly downregulated in 
human CSps and IICSps. However, in a recent work [132], PCR array analysis of the 
gene expression of ECM and adhesion molecules in human cells cultured as CSps or 
monolayers, has shown that 12 out of 84 ECM and adhesion genes examined were 
up-regulated more than 4-fold in CSps relative to monolayer cells, including 
COL14A1, COL7A1, ITGA2, LAMB1, LAMB3, MMP3, MMP10, MMP11, MMP13, SELE, 
PECAM1 and SPP1, while Cadherin type 1 (CDH1) was the sole gene up-regulated in 
cells cultured as monolayers.  
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Figure 3.7. Expression levels of endothelial (Tie2, Cdh5), epithelial (Cdh1), epicardial (Wt1, Tbx18) 
and mesenchymal (SMA, Vimentin) markers, in human CSps versus EDCs.  
 
Figure 3.8. RT-PCR analyses of endothelial markers (Cdh5, Tie2) in EDCs, CSps, CDCs and IICSps. 
Bottom panels: average expression values in EDCs and CSps from different harvests (P1, P2, P3) 
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Figure 3.9. RT-PCR analyses of embryonic epicardial markers (Wt1, Tbx18) in EDCs, CSps, CDCs and IICSps. 
Bottom panels: average expression values in EDCs and CSps from different harvests (P1, P2, P3) 
 
Figure 3.10. RT-PCR analyses of Snai1 (EMT marker) and Cdh1 (epithelial marker) in EDCs, CSps, CDCs and 
IICSps. Bottom panels: average expression values in EDCs and CSps from different harvests (P1, P2, P3) 
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Figure 3.11. RT-PCR analyses of mesenchymal markers (SMA, Vimentin) in EDCs, CSps, CDCs and IICSps. 
Bottom panels: average expression values in EDCs and CSps from different harvests (P1, P2, P3) 
 
Figure 3.12. Summarizing graph to show the gene expression trends in the four different cell populations: 
EDCs, CSps, CDCs, IICSps.  
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Discussion and future directions 
Based on these data, the reduced expression of SMA and the increased levels of 
adhesion molecules in CSps, including Tie2 and Cdh5, may suggest that SMA+ cells 
(embriologically derived from the epicardium) take part in CSps formation through 
a MEndT or MET process, with consequent reactivation of markers of the 
embryonic epicardium, such as Tbx18 and Wt1. Recent works, indeed, have 
demonstrated that MET is a fundamental step to initiate cellular reprogramming 
[133, 134]. Reactivation of Wt1 in the CSp may in turn, induce EMT as suggested by 
the increased expression of Snail. In fact Wt1 is known to be a central mediator of 
EMT that leads to the generation of mesenchymal cardiovascular progenitor cells in 
the epicardium and during ESCs differentiation, through direct reactivation of the 
Snail transcription factor and inhibition of E-cadherin [115].  Intriguingly EMT has 
been proven to be important to induce a stem-cell phenotype even in other tissues. 
For example, when exposed to TGF-β1 for 12 days or by over-expressing the EMT-
inducing transcription factors Snail or Twist, normal mammary epithelial cells could 
be induced to adopt the CD44high/CD24low expression profile, typical of stem-like 
cells, with an enhanced ability to form “mammospheres” and the potential to 
differentiate into cells expressing lineage-specific markers of myoepithelial or 
luminal epithelial cells [50, 51]. Moreover chronic exposure to TGF-β [135] induced 
EMT, accompanied by a de-differentiation process in both a non-transformed 
model, such as human fetal hepatocytes and in human hepatic cancer cells, Hep3B, 
as shown by: the loss of expression of hepatic proteins; the diminished expression 
of liver enriched transcription factors typical of mature hepatocytes, such as HNF4α 
or HNF1α; the increase in the expression of liver transcription factors characteristic 
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of early embryonic stages, such as HNF3β and of proteins described as markers of 
hepatic stem cells, such as CK7, Thy1, c-Kit and/or EpCAM. 
Furthermore, as we mentioned before, EMT/EndMT processes occurring during 
embryonic development, create cells that act as progenitors of many different 
tissues from the mesoderm or neural crest. In the heart four different controlled 
transition layer occur during organogenesis, including that involving the epicardium 
[27], each generating a distinct set of cardiovascular progenitor cells that 
differentiate into the cellular components of the mature heart. These processes 
have been already shown to be re-activated in response to cardiac injury, mainly 
contributing to vasculogenesis and fibrosis.  
 Therefore it is plausible that these same transitions occur in CSps, induced by the 
culture conditions or by the ischemic gradient present in these 3D structures. In this 
view, a model/hypothes of spontaneous in vitro reprogramming process could be 
proposed (fig.3.13) as a starting point for the future steps. In fact, a better 
understanding of the relevance of these processes in CSps formation will be 
essential to improve the knowledge of their biological regulatory pathways and 
potentially their therapeutic effect, since it will give us insights on how to modulate 
their differentiation potential, in order to promote and/ot maintain a cardiogenic 
destiny rather than a fibrogenic one, which could be physiologically favored in the 
hostile inflammatory environment of the infarcted heart.  
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Figura 3.13. Proposed model. The reduced expression of SMA and the increased expression of Tie2 
and Cdh5 in CSps compared to EDCs, may suggest the occurrence of End/EMT, probably in SMA
+
 
cells (embryologically derived from epicardium), with re-activation of embryonic epicardial genes 
(Tbx18, Wt1) during CSps formation. Wt1 is known to be an active mediator of the EMT that leads to 
the generation of mesenchymal multipotent progenitor cells from epicardial cells, by Snai1 
activation and inhibition of Cdh1. In CSps, Snai1 is upregulated and Cdh1 is downregulated 
compared to monolayer cells, suggesting the possible occurrence of EMT (probably due also to the 
hypoxic gradient inside the CSps) that may generate progenitor cells. A better understanding of the 
relevance of these processes in CSps formation will be essential to improve their therapeutic effect, 
since it will give insights on how to modulate their differentiation potential in order to promote a 
cardiogenic outcome rather than a fibrogenic one. 
 86 
 For this propose, many questions remain to be answered. It is interesting to see 
how the expression of the examined genes varies consistently between 3D 
structures and monolayer cells, confirming the importance of the niche-like 
structure of CSps, but CSps consist of different cell types, thus we cannot yet 
univocally determine which cells are involved in these transitions. The use of 
conditional Wt1CreERT2 Z/EG transgenic mice [40] and of a reporter construct to 
transfect human explants will help us understand which cells actually reactivate 
Wt1, how they are involved in CSps formation and it will allow us to trace their fate 
both in vitro and in vivo, after CSps or CDCs injection into the infarct border zone of 
syngeneic mice subjected to LAD ligation. In vitro treatments with molecules known 
to be important regulators of EMT/MET, such as TGFβ, Metmorfin, BMP7, miR200-
205, will give us information on how these transitions are relevant in our cellular 
model. A PCR array will be performed to analyze a larger number of genes known 
to be involved in EMT and reprogramming and the production of relevant proteins 
will be confirmed by ELISA and Western Blot.  Analysis by transmission electron 
microscopy will give us important hints on the morphology and phenotype of single 
cells inside the CSps and the laser capture microdissection technique, combined to 
gene expression analysis, will allow highlighting differences between the CSp’s core 
and periphery, that may be due to the hypoxic gradient present in the 3D structure, 
which, as already mentioned, is a well known EMT-inducing factor itself. 
In conclusion, CSps represent a valuable method to isolate CPCs, since the 3D 
structure ensures a niche-like microenvironment which promotes the maintenance 
of a stemness phenotype in the core, while conferring higher engraftment in vivo 
and resistance to ischemic stress. As mentioned above, de-differentiation of 
cardiomyocytes, recruitment of circulating cells deriving from the bone marrow, 
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controlled layer/lineage transitions or the presence of remnant cells from 
embryonic development are considered to be potential sources of CPCs.  
Our work ruled out a significant contribution of cardiomyocyte to CSps formation, 
while evidencing the involvement of epicardial-deriving cells, reactivating their 
embryonic developmental program in the 3D niche-like microenvironment of the 
CSp. Thus the information acquired represents a starting point for a better 
evaluation not only of the biological meaning of heart-tissue-derived cardiac 
regenerative cells in the form of CSps, but also for the prevision of  their fate in vivo 
once translated into clinic as therapeutic mediators in cardiac cell therapy. 
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NON STANDARD ABBREVIATION AND ACRONYMS 
ACM: adult cardiomyocyte 
AV: atrioventricular 
BM: bone marrow 
CDC: CSp-derived cell 
CEM: complete explants medium 
CMPC: cardiomyocytes progenitor cell 
CPC: cardiac progenitor cell 
Cr: Cripto 
CSC: cardiac stem cell 
CSM: cardiosphere medium 
CSp: cardiosphere 
DAB: 3,3'-Diaminobenzidine chromogen 
EB: embryoid body 
EDC: explant derived cell 
EPDC: epicardial derived progenitor cell 
ESC: embryonic stem cell 
EMT: Epithelial-to- mesenchymal transition 
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EndMT: endothelial-to-mesenchymal transition 
Fb: fibroblast 
H3P: histone 3 phosphorylated 
IICSp: secondary CSp 
MET: mesenchymal-to-epithelial transition 
MF20: meromyosin 
MHC: myosin heavy chain 
MI: myocardial infarction 
MLC2v: myosin light chain 2v 
NC: neural crest 
SMA: smooth muscle actin 
SMC: smooth muscle cell 
TAM: Tamoxifen 
TnT: troponin I 
Tmsb4: Thymosin β4 
Wt1: Wilm’s tumor-1 
vWF: von Willembrand factor 
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